国家基本药物制度的现状及其完善对策探讨  

National Essential Drug Policy:Status Quo and Countermeasure

作　　者：覃正碧[1] 汪志宏[2] 程刚[3] 李元启 左小平 卢祖洵[1] 向继洲[1] 

机构地区：[1]华中科技大学同济医学院公共卫生学院,武汉市4300032 [2]华中科技大学同济医学院附属梨园医院,武汉市430071 [3]国家食品药品监督管理局药品评价中心,北京市100045 [4]湖北省食品药品监督管理局/药品不良反应监测中心,武汉市430071 [5]湖北省恩施州食品药品监督管理局,恩施市445000

出　　处：《中国药房》2008年第14期1041-1044,共4页China Pharmacy

摘　　要：目的:完善国家基本药物制度,满足公众的健康医疗需求。方法:采用文献研究、对比分析方法,阐述国家基本药物制度存在的问题,提出完善国家基本药物制度的对策。结果:我国虽制定了与《国家基本药物目录》相关的药物政策,但与世界卫生组织倡导的基本药物目标尚有较大差距,且存在法规体系不健全、政府宏观调控乏力、公众对基本药物认识不够、民众可获得基本药物不公平、基本药物制度建设滞后等问题。结论:我国基本药物法规体系亟待完善,民众对基本药物的认知和可获得性有待提高。应进一步提高基本药物的法律地位,强化《国家基本药物目录》的科学遴选、使用与监管,从而保障公众基本用药需求。OBJECTIVE： To improve the national essential drug policy to meet the public demand on the public health care. METHODS： The problems existing in the national essential drug policy were analyzed by reviewing literature using comparative analysis. Some countermeasures were come up with for the system. RESULTS： The policy related to National Essential Drug List has been established in our country, but it still lags far behind the goal of essential drugs set by WTO. Some problems such as the imperfect laws and regulations, lack of the governmental macro-control, public＇ s lack of knowledge on the essential drugs, populace＇s unfair access to essential drugs, the backward construction of essential drug system etc can still be seen. CONCLUSION： The laws and regulations on national essential drugs should be evolved, people＇s recognition on and access to the essential drugs remain to be improved. The legal position of the essential drugs should be enhanced, and the selection, use and supervision of National Essential Drug List should be intensified to safeguard public＇s demand on medication.

关 键 词：国家基本药物目录 制度 政策 对策 

分 类 号：R95[医药卫生—药学]